Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
P/S ratio for Enanta Pharmaceuticals, Inc. (ENTA)
P/S ratio as of 2024: 3.24
According to Enanta Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.24. At the end of 2023 the company had a P/S ratio of 2.96.
P/S ratio history for Enanta Pharmaceuticals, Inc. from 2010 to 2024
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2024 | 3.24 |
| 2023 | 2.96 |
| 2022 | 12.40 |
| 2021 | 11.80 |
| 2020 | 7.45 |
| 2019 | 5.73 |
| 2018 | 8.41 |
| 2017 | 8.68 |
| 2016 | 5.71 |
| 2015 | 4.19 |
| 2014 | 15.21 |
| 2013 | 7.00 |
| 2012 | 0.48 |
| 2011 | 0.48 |
| 2010 | 9.62 |